Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 15/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98484 | 0.79 | LMNA (0.39) | FDPSGGPS1LMNALPAR1LPAR3 | |
| SCHEMBL2782812 | 0.73 | GGPS1 (0.59) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL9393428 | 0.73 | GGPS1 (0.59) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL6307341 | 0.70 | FDPS (0.45) | FDPSGGPS1LMNASMPD1LPAR1 | |
| SCHEMBL513412 | 0.70 | FDPS (0.31) | FDPS | |
| SCHEMBL19386024 | 0.70 | FDPS (0.43) | FDPSGGPS1LMNASMPD1 | |
| SCHEMBL6296955 | 0.65 | FDPS (0.43) | FDPSGGPS1LMNASMPD1LPAR1 | |
| SCHEMBL1768259 | 0.65 | FDPS (0.43) | FDPSGGPS1LMNASMPD1LPAR1 | |
| SCHEMBL246809 | 0.65 | FDPS (0.43) | FDPSGGPS1LMNASMPD1LPAR1 | |
| SCHEMBL8718782 | 0.65 | GGPS1 (0.50) | FDPSGGPS1LMNASMPD1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| WO-2010123599-A9 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2010123599-A2 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-1740556-A1 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050239751-A1 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005097760-A1 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239751-A1 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | HAVCR2, HCCS, AADAC | FDPS 49/4885GGPS1 199/4885LMNA 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.